Davidson Kempner Expects Thermo Fisher Scientific's Current Offer for QIAGEN N.V. to Fail

Davidson Kempner Expects Thermo Fisher Scientific's Current Offer for QIAGEN N.V. to Fail

PR Newswire

LONDON, July 28, 2020

LONDON, July 28, 2020 /PRNewswire/ --

  1. Davidson Kempner European Partners, LLP is the sub-adviser to Davidson Kempner Capital Management LP which acts as the discretionary investment manager to various funds which represent 5.1% of the share capital of QIAGEN N.V. (the "Company")
  2. Davidson Kempner believes the standalone fair value for the Company to be €48-52 per share
  3. Davidson Kempner will not be tendering its shares and fully expects the current offer to fail
  4. Davidson Kempner has launched a website containing supporting information and evidence: https://unlockthevalueofqiagen.com/

 

For media enquiries:
Greenbrook
Andrew Honnor, Rob White, Fanni Bodri
Email: davidsonkempner@greenbrookpr.com 
Tel: +44 (0) 20 7952-2000  

 

Voltar noticias em Inglês